Latest filing published 01 Apr 2021 for Pandion Therapeutics, Inc., €4.3M.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Alan L. Crane appears in our data through filings on Pandion Therapeutics, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 21 July 2020 to 1 April 2021, the count stands at 12 filings.
No open-market sale appears; the market trades are 3 purchases worth €782k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
The median purchase comes to €218k. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.
On 1 April 2021 came the latest disclosure, a transaction for €4.3M in Pandion Therapeutics, Inc. The last purchase on record was published on 21 July 2020, which is 2,285 days ago. Half of the filings or more reach the SEC (Form 4) feed on the day of the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Same trade as the filing by Polaris Partners GP VIII, L.L.C., counted once
Same trade as the filing by Polaris Partners GP VIII, L.L.C., counted once
12 of 10 declarations